H.C. Wainwright analyst Joseph Pantginis has reiterated their bullish stance on ATXS stock, giving a Buy rating today.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Joseph Pantginis’s rating is based on Astria Therapeutics’ promising clinical developments and strong financial position. The company has recently announced the initiation of the ALPHA-ORBIT Phase 3 clinical study for navenibart, a monoclonal antibody inhibitor aimed at treating hereditary angioedema (HAE). This pivotal trial is designed to evaluate the efficacy and safety of various dosing regimens, with the potential to offer flexible treatment options for patients, which is a significant quality of life metric.
Additionally, Astria’s STAR-0310, an OX40 inhibitor, is undergoing a Phase 1a clinical trial to assess its safety and efficacy in treating atopic dermatitis. The company’s financial health is robust, with $295.1 million in cash, providing a runway into mid-2027. These factors, combined with the potential for navenibart to become a first-choice preventative treatment for HAE, underpin Pantginis’s Buy rating for Astria Therapeutics.
In another report released today, Citizens JMP also maintained a Buy rating on the stock with a $25.00 price target.